Status:

COMPLETED

A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program

Lead Sponsor:

Indiana University

Collaborating Sponsors:

National Human Genome Research Institute (NHGRI)

Conditions:

Adverse Drug Reaction

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The INGenious trial will prospectively enroll a total of 6,000 patients, with 2,000 patients assigned to a pharmacogenetic testing arm and 4,000 to a control arm who will be followed, but not tested. ...

Detailed Description

Indiana University School of Medicine and the Indiana University Institute of Personalized Medicine in collaboration with the Eskenazi Health and IUH Systems will be conducting a NIH funded randomized...

Eligibility Criteria

Inclusion

  • Patients will be eligible for inclusion if they are prescribed one of the 27 index medications for the first time, defined as there being no recorded prescription in the Eskenazi, Indiana University Health or Indiana Patient Care (INPC) system over the past year. The inclusion criteria that will be adhered to will be:
  • Able and willing consent to participation in the trial;
  • Adults aged 18 and over;
  • Receiving care at Eskenazi Health or Indiana University Health Systems for 1 year or more;
  • Prescribed an index medication.
  • No documented prescription of the index medication for the past year.
  • The study limit of enrollment (500) for that medication has not been reached
  • A single tube of whole blood can be obtained, and
  • Able to follow study procedures. -

Exclusion

  • No subject will be excluded from the study on the basis of ethnicity or race. We will include all minorities.
  • Patients will be excluded if they:
  • Cannot or do not consent to participate;
  • are unable to provide 5cc of whole blood, or it cannot be obtained;
  • if they are an employee or student under the supervision of any of the investigators.

Key Trial Info

Start Date :

March 1 2015

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 3 2019

Estimated Enrollment :

4465 Patients enrolled

Trial Details

Trial ID

NCT02297126

Start Date

March 1 2015

End Date

May 3 2019

Last Update

January 8 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Eskenazi Health System

Indianapolis, Indiana, United States, 46250